CSIR) and Hyderabad-based Laxai Life Sciences will now undertake a two-arm phase-II clinical trial to ascertain safety and efficacy of the drug in improving clinical outcomes during the treatment of Covid-19 patients.
CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu will be the partner institutes in this trial.Back in January, researchers in Canada had first discovered that Colchicine could be used to Covid-19 patients, where is reduced chances of death and hospitalisation by 21 per cent in comparison to placebo.
Colchicine is originally used to treat gout, a complex form of arthritis that occurs when too much uric acid accumulates in joints.